The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results - Sallman, D; Asch, A; Kambhampati, S; Al Malki, M; Zeidner, J; Donnellan, W; Lee, D; Vyas, P; Jeyakumar, D; Mannis, G; Tanaka, T; Chai-Ho, W; et al. (Elsevier, 2021)